|Bid||0.00 x 3000|
|Ask||0.00 x 1800|
|Day's Range||34.89 - 35.26|
|52 Week Range||31.43 - 48.25|
|Beta (5Y Monthly)||0.34|
|PE Ratio (TTM)||35.37|
|Forward Dividend & Yield||1.89 (5.34%)|
|Ex-Dividend Date||May 14, 2020|
|1y Target Est||N/A|
GlaxoSmithKline is testing two vaccines that could protect newborns and people over age 60 from RSV, a virus that has defied vaccine developers for years.
GlaxoSmithKline (GSK) closed at $35.35 in the latest trading session, marking a -1.91% move from the prior day.
GlaxoSmithKline said it would move its experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing, encouraged by mid-stage trial results. RSV vaccine development has been fraught with setbacks for decades but the pharma industry is gearing up to bring a first inoculation to market over the next few years. GSK said a Phase I/II trial with about 1,000 healthy adults aged 60-80 showed that the vaccine prompted a "robust" increase in antibodies and immune cells one month after injection, indicating a stimulated immune system.